ABT-869
货号:
13653-1mg 基本售价:
686.0 元 规格:
1 mg
产品信息
概述货号 | 13653-1mg |
描述 | Receptor tyrosine kinases (RTKs) mediate critical signaling transduction pathways important for cell survival, growth, and differentiation. Whereas aberrant tyrosine kinase signaling is correlated with the progression of various cancers, RTK inhibitors are useful as cancer therapy agents. ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families (e.g., KDR, FLT1, FLT3, FLT4, CSF-1R, and KIT) demonstrating IC50 values ranging from 4-190 nM.1 ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases (IC50s > 1 μM).1 ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells (acute myeloid leukemia cell lines harboring RTK mutations; IC50s = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage.2 In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.3 |
别名 | Linifanib; |
性能供应商 | Cayman |
应用文献 |
1.Albert, D.H.,Tapang, P.,Magoc, T.J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 5(4), 995-1006 (2006). 2.Shankar, D.B.,Li, J.,Tapang, P., et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: Inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109, 3400-3408 (2007). 3.Zhou, J.,Goh, B.C.,Albert, D.H., et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside. J.Hematol.Oncol. 2(33), (2009).
|
运输条件 | Wet ice in continental US; may vary elsewhere |
存放说明 | -20 |
纯度 | ≥98% |
计算分子量 | 375.4 |
分子式 | C21H18FN5O |
CAS号 | 796967-16-3 |
稳定性 | ≥ 1 year |
声明本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。 |